The impact of starting dose on overall survival in myelofibrosis patients treated with ruxolitinib: A prospective real‐world study on AIFA monitoring registries
British Journal of Haematology · 2025-01 · 206 (1) · 172-179
DOI: 10.1111/bjh.19812 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift British Journal of Haematology, online erschienen am 03.10.2024. Verfasst von Massimo Breccia und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational and Precision Medicine, Sapienza University, Rome, Italy. Hauptthemen laut MEDLINE: Nitriles, Primary Myelofibrosis, Pyrazoles, Pyrimidines. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Abstract (Originalsprache)
Ruxolitinib is a JAK1/JAK2 inhibitor approved for the treatment of myelofibrosis (MF)‐related splenomegaly or symptoms. The recommended starting dose depends on platelet count, regardless of haemoglobin level at baseline. In the recent years, an overall survival (OS) advantage was reported in patients treated with ruxolitinib compared with best available therapy. We analysed a large Italian cohort of 3494 patients identified by Agenzia Italiana del Farmaco (AIFA) monitoring registries. Of them, 2337 (66.9%) started at reduced dose: these patients were older (median age 70 vs. 67), with increased incidence of large splenomegaly (longitudinal diameter 20 vs. 19.1 cm, median volume 1064 cm 3 vs. 1016 cm 3 ), with higher IPSS risk (30.9% vs. 26.1%), and worse ECOG score (more than 1 in 14.3% vs. 9.8%). After balancing for baseline characteristics, Kaplan–Meier analysis showed a median OS of 78.2 months (95% CI 65.9–89) for patients who started at full dose and 52.6 (95% CI 49–56.6) months for patients who started with reduced dose ( p < 0.001). Group analysis also showed a substantial difference in patients with intermediate‐2 and high IPSS risk. The majority of MF patients in real‐world analysis started with a reduced dose of ruxolitinib, which is associated with less favourable outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Translational and Precision Medicine, Sapienza University, Rome, Italy.
- AIFA Italian Medicines Agency, Rome, Italy.
- IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy.
- Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.
- Hematology with BMT Unit, A.O.U. "G. Rodolico-San Marco", Italy University of Catania, Catania, Italy.
- Università Degli Studi di Napoli Federico II, Naples, Italy.
ORCID-Profile: Massimo Breccia, Francesca Palandri, Francesco Passamonti, Pier Paolo Olimpieri, Paola Guglielmelli, Paolo Corradini
Zitieren
APA
Breccia, M., Celant, S., Palandri, F., Passamonti, F., Olimpieri, P. P., Summa, V., Guarcello, A., Palumbo, G. A., Pane, F., Guglielmelli, P., Corradini, P., & Russo, P. (2025). The impact of starting dose on overall survival in myelofibrosis patients treated with ruxolitinib: A prospective real‐world study on AIFA monitoring registries. British Journal of Haematology, 206(1), 172-179. https://doi.org/10.1111/bjh.19812
Vancouver
Breccia M, Celant S, Palandri F, Passamonti F, Olimpieri PP, Summa V, et al. The impact of starting dose on overall survival in myelofibrosis patients treated with ruxolitinib: A prospective real‐world study on AIFA monitoring registries. British Journal of Haematology. 2025;206(1):172-179. doi:10.1111/bjh.19812
BibTeX
@article{Breccia2025,
author = {Breccia, Massimo and Celant, Simone and Palandri, Francesca and Passamonti, Francesco and Olimpieri, Pier Paolo and Summa, Valentina and Guarcello, Annalisa and Palumbo, Giuseppe Alberto and Pane, Fabrizio and Guglielmelli, Paola and Corradini, Paolo and Russo, Pierluigi},
title = {The impact of starting dose on overall survival in myelofibrosis patients treated with ruxolitinib: A prospective real‐world study on AIFA monitoring registries},
journal = {British Journal of Haematology},
year = {2025},
volume = {206},
number = {1},
pages = {172--179},
doi = {10.1111/bjh.19812}
}
EUVIMED